Zhang, Zhao http://orcid.org/0000-0002-3757-8469
Lee, Joo-Hyung
Ruan, Hang
Ye, Youqiong http://orcid.org/0000-0001-8332-4710
Krakowiak, Joanna http://orcid.org/0000-0001-9873-0746
Hu, Qingsong
Xiang, Yu
Gong, Jing
Zhou, Bingying
Wang, Li
Lin, Chunru
Diao, Lixia
Mills, Gordon B.
Li, Wenbo
Han, Leng http://orcid.org/0000-0002-7380-2640
Funding for this research was provided by:
Cancer Prevention and Research Institute of Texas (RR150085)
Article History
Received: 28 November 2018
Accepted: 16 September 2019
First Online: 8 October 2019
Competing interests
: G.B.M. has sponsored research support from AstraZeneca, Critical Outcomes Technology, Karus, Illumina, Immunomet, Nanostring, Tarveda and Immunomet and is on the Scientific Advisory Board for AstraZeneca, Critical Outcomes Technology, ImmunoMet, Ionis, Nuevolution, Symphogen, and Tarveda. The other authors declare no competing interests.